C4 Therapeutics, Inc.
CCCC
$2.53
-$0.08-3.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 34.24M | 39.78M | 35.58M | 33.67M | 29.38M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.24M | 39.78M | 35.58M | 33.67M | 29.38M |
| Cost of Revenue | 117.62M | 115.18M | 110.64M | 108.52M | 105.02M |
| Gross Profit | -83.38M | -75.39M | -75.05M | -74.85M | -75.65M |
| SG&A Expenses | 40.24M | 41.17M | 42.12M | 42.05M | 40.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 157.86M | 156.34M | 152.76M | 150.56M | 145.84M |
| Operating Income | -123.62M | -116.56M | -117.18M | -116.90M | -116.46M |
| Income Before Tax | -111.45M | -103.15M | -105.19M | -105.22M | -106.59M |
| Income Tax Expenses | 131.00K | 131.00K | 131.00K | 277.00K | 1.28M |
| Earnings from Continuing Operations | -111.58 | -103.28 | -105.32 | -105.50 | -107.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -111.58M | -103.28M | -105.32M | -105.50M | -107.87M |
| EBIT | -123.62M | -116.56M | -117.18M | -116.90M | -116.46M |
| EBITDA | -121.63M | -114.73M | -115.36M | -115.13M | -114.69M |
| EPS Basic | -1.58 | -1.47 | -1.52 | -1.70 | -1.90 |
| Normalized Basic EPS | -1.01 | -0.96 | -0.96 | -1.08 | -1.18 |
| EPS Diluted | -1.58 | -1.47 | -1.52 | -1.70 | -1.90 |
| Normalized Diluted EPS | -1.01 | -0.96 | -0.96 | -1.08 | -1.18 |
| Average Basic Shares Outstanding | 282.07M | 279.88M | 277.48M | 258.12M | 237.71M |
| Average Diluted Shares Outstanding | 282.07M | 279.88M | 277.48M | 258.12M | 237.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |